One-year treatment of chronic urticaria with mizolastine: Efficacy and safety

Journal of the European Academy of Dermatology and Venereology

Volumn 14, Issue 2, 2000, Pages 83-90

  Lorette, G ^a   Giannetti, A ^b   Pereira, Rs ^c   Leynadier, F ^d   Murrieta Aguttes, M ^e  

^a SERVICE DE DERMATOLOGIE   (France)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^c CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^d HÔPITAL TENON   (France)

^e SANOFI   (France)

Author keywords

Chronic urticaria; Electro cardiography; Histamine H1 receptor antagonists; Mizolastine; QT interval; Ventricular repolarization

Indexed keywords

HISTAMINE H1 RECEPTOR ANTAGONIST; MIZOLASTINE; PLACEBO;

ADULT; ADVERSE DRUG REACTION; ALLERGIC RHINITIS; ANGIONEUROTIC EDEMA; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CHRONIC URTICARIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; DRUG SENSITIVITY; ELECTROCARDIOGRAM; FEMALE; HEART; HEART REPOLARIZATION; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; MEDICAL ASSESSMENT; MULTICENTER STUDY; PALLIATIVE THERAPY; PARAMETER; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; QT INTERVAL; SIDE EFFECT;

ADULT; BENZIMIDAZOLES; CHRONIC DISEASE; FEMALE; HISTAMINE H1 ANTAGONISTS; HUMANS; MALE; URTICARIA;

EID: 0034426825     PISSN: 09269959     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1468-3083.2000.00014.x     Document Type: Article

References (39)

1. Chronic urticaria
2. Urticaria: Current therapy
3. Urticaria: Recognition, causes and treatment
4. Urticaria and angioedema: Diagnosis and evaluation
5. Drug therapy of chronic urticaria and angioedema
6. 1 antihistamine
7. Mechanisms of experimental bronchopulmonary hyperresponsiveness as related to eosinophils
8. Inhibitory effect of mizolastine on 5-lipoxygenase
9. Anti-inflammatory properties of mizolastine after oral administration on arachidonic acid-induced cutaneous reaction in the rat
10. Effect of mizolastine on visceral sensory afferent sensitivity and inflammation during experimental colitis
11. Inhibitory effect of oral mizolastine 10 mg o.d. on in vivo antigen-induced soluble ICAM-1 release in human skin (skin chamber technique)
12. Inhibition of histamine-induced skin wheal and flare after 5 days of mizolastine
13. Assessment of the anticho linergic effect of the new antihistamine mizolastine in healthy subjects
14. The psychomotor and cognitive effects of a new antihistamine, mizolastine, compared to terfenadine, triprolidine and placebo in healthy volunteers
15. Effects of mizolastine, a new antihistamine, on psychomotor performance and memory in elderly subjects
16. Antihistamines in urticaria
17. Efficacy of mizolastine, a new antihistamine, compared with placebo in the treatment of chronic idiopathic urticaria
18. Mizolastine (MZL) versus placebo (PLC) in chronic idiopathic urticaria
19. A comparative study of mizolastine 10 mg vs loratadine 10 mg in chronic idiopathic urticaria: Focussing on the effect on histamine induced wheals and flares
20. Efficacy and safety of mizolastine in a placebo-controlled comparison with loratadine in chronic idopathic urticaria
21. Effect of mizolastine vs placebo in acquired cold induced urticaria (ACIU): The cold stimulation time test (CSTT)
22. Mizolastine: A review of its use in allergic rhinitis and chronic idiopathic urticaria
23. Terfenadine-ketoconazole interaction. Pharmacokinetic and electrocardiographic consequences
24. Risk of developing lif-threatening ventricular arrhythmia associated with terfenadine in comparison with over the counter antihistamines, ibuprofen and clemastine
25. Rate-corrected QT interval duration: Techniques and limitations
26. QT prolongation and sudden cardiac death in patients with alcoholic liver disease
27. Chronic urticaria: Pathophysiology and treatment approaches
28. 1 antagonists in the treatment of chronic idiopathic urticaria
29. Comparative efficacy and safety of loratadine and placebo in chronic idiopathic urticaria
30. A double blind, randomized, placebo controlled, parallel study comparing the safety and efficacy of terfenadine 60 mg b.i.d. to hydroxyzine 25 mg q.i.d. administered for 6-12 weeks in the treatment of chronic idiopathic urticaria
31. Double-blind multicentre comparative study of ebastine, terfenadine and placebo in the treatment of chronic idiopathic urticaria in adults
32. Lack of subsensitivity to mizolastine over 8-week treatment
33. 1-receptor antagonist: Results of a pool of 30 clinical phase II, III, double blind studies
34. Risk of selected serious cardiac events among new users of antihistamines
35. Cardiac safety profile of mizolastine: A pooled analysis of 4 double blind studies
36. 1-receptor antagonist
37. 1 antihistamine and erythromycin
38. Lack of effect of mizolastine on the safety and pharmacokinetics of digoxin administered orally in repeated doses to healthy volunteers
39. Cardiac safety of antihistamines